Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey

Psychiatr Serv. 2024 Feb 1;75(2):182-185. doi: 10.1176/appi.ps.20230087. Epub 2023 Aug 24.

Abstract

Objective: This report aimed to assess how accountable care organizations (ACOs) addressed ongoing opioid use disorder treatment needs over time.

Methods: Responses from the 2018 (N=308 organizations) and 2022 (N=276) National Survey of Accountable Care Organizations (response rate=55% in both years) were used to examine changes in availability of medication for opioid use disorder (MOUD) among ACOs with Medicare and Medicaid contracts.

Results: The percentage of respondents offering at least one MOUD grew from 39% in 2018 to 52% in 2022 (p<0.01). MOUDs were more likely to be available in 2022 among ACOs with (vs. without) in-network substance use treatment facilities (80% vs. 33%, p<0.001). The percentage of 2022 respondents who reported offering MOUD was similar in states with high versus low opioid overdose mortality rates.

Conclusions: Despite growing availability of MOUD among ACOs, nearly half reported not offering any MOUD in 2022, and the availability of MOUD did not increase with treatment need.

Keywords: Accountable care organizations; Drug abuse; Public health.

MeSH terms

  • Accountable Care Organizations*
  • Aged
  • Buprenorphine* / therapeutic use
  • Humans
  • Medicaid
  • Medicare
  • Opioid-Related Disorders* / drug therapy
  • United States

Substances

  • Buprenorphine